Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25883278 | 1.00 | SRC (0.48) | SRCL3MBTL1TDP1HPGDKDM4E | |
| SCHEMBL27836558 | 0.81 | SRC (0.52) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL80417 | 0.81 | SRC (0.52) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL2303782 | 0.81 | SRC (0.52) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL873578 | 0.79 | SRC (0.55) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL17305220 | 0.76 | L3MBTL1 (0.50) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL27881894 | 0.76 | SRC (0.47) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL2497223 | 0.76 | L3MBTL1 (0.50) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| Phosphoric Acid SCHEMBL29974621 | 0.75 | SRC (0.46) | SRCL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL17860514 | 0.75 | SRC (0.46) | SRCL3MBTL1TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230264164-A1 | HOMOPOLYMER ENCODED NUCLEIC ACID MEMORY | TRILINK BIOTECHNOLOGIES, LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230241257-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2023-08-03 | — | — | US | disclosed |
| US-10035774-B2 | Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds | MERCK SHARP & DOHME CORP. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180193478-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9821493-B2 | Microwave dipolar heating of energetic polymers for carbon fiber-matrix separation | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160279834-A1 | MICROWAVE DIPOLAR HEATING OF ENERGETIC POLYMERS FOR CARBON FIBER-MATRIX SEPARATION | CRESTLINE DIRECT FINANCE, L.P. | 2016-09-29 | — | — | US | disclosed |
| US-20160222423-A1 | ENZYME-CATALYZED ENANTIOSELECTIVE AZIRIDINATION OF OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-08-04 | — | — | US | disclosed |
| US-8524814-B2 | Phosphonate bonding compositions | HENKEL IRELAND LIMITED (DE) | 2013-09-03 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120202091-A1 | PHOSPHONATE BONDING COMPOSITIONS | LOCTITE (R&D) LIMITED (IE) | 2012-08-09 | — | — | US | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | SRC 294/4885L3MBTL1 3775/4885TDP1 3985/4885 |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | SRC 4196/4885L3MBTL1 2852/4885TDP1 1008/4885 |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | UROD, PEPD, CMPK1 | SRC 3308/4885L3MBTL1 4741/4885TDP1 4301/4885 |
| US-20230241257-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | BTD, HLCS, BRD4 | SRC 3321/4885L3MBTL1 362/4885TDP1 4134/4885 |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | SRC 95/4885L3MBTL1 3893/4885TDP1 2565/4885 |
| US-10035774-B2 | Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds | UROD, PEPD, CMPK1 | SRC 3308/4885L3MBTL1 4741/4885TDP1 4301/4885 |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | SRC 4109/4885L3MBTL1 3577/4885TDP1 3078/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | SRC 3180/4885L3MBTL1 4091/4885TDP1 1665/4885 |
| US-20180193478-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | SRC 2609/4885L3MBTL1 3555/4885TDP1 1781/4885 |
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | SRC 3906/4885L3MBTL1 1287/4885TDP1 4071/4885 |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | SRC 3869/4885L3MBTL1 3428/4885TDP1 3329/4885 |
| US-20120202091-A1 | PHOSPHONATE BONDING COMPOSITIONS | NOXO1, DDO, PTK2 | SRC 707/4885L3MBTL1 4527/4885TDP1 729/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | SRC 2609/4885L3MBTL1 3555/4885TDP1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.